Sunlenca Product Label
Interaction Color Code
Clinical Bottom Line
Do not coadminister: increased levels of atazanavir
Drug 1
Drug 1 dose
300 mg orally x 1
Drug 1 effect
AUC increased 321%; Cmax increased 560%
Drug 2
Drug 2 dose
300/150 mg daily (fed state)
Drug 2 effect
Not reported
Mechanism
Inhibition of CYP3A4, UGT1A1, and P-gp by atazanavir and cobicistat
Clinical Effects
Potential for increased atazanavir adverse effects (e.g. hyperbilirubinemia, gastrointestinal effects).
Management
Use alternative agents
Info Source
